Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSE | P14091 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16853789 | 0.90 | USP30 (0.44) | USP30GPR119PDE4BSTSPDE4D | |
| SCHEMBL17631637 | 0.87 | USP30 (0.44) | USP30GPR119 | |
| SCHEMBL17631639 | 0.87 | USP30 (0.44) | USP30GPR119 | |
| SCHEMBL12801187 | 0.85 | USP30 (0.49) | USP30GPR119PDE4BPDE4DPDE4A | |
| SCHEMBL16100303 | 0.78 | USP30 (0.51) | USP30GPR119KDM1APRMT5WDR77 | |
| SCHEMBL16611414 | 0.78 | USP30 (0.51) | USP30GPR119STSAAK1 | |
| SCHEMBL20934895 | 0.76 | TBK1 (0.37) | USP30GPR119 | |
| SCHEMBL532111 | 0.76 | PDE4B (0.59) | USP30GPR119PDE4BSTSPDE4D | |
| SCHEMBL13717948 | 0.76 | GPR119 (0.58) | USP30GPR119PDE4BPDE4DPDE4A | |
| SCHEMBL24904180 | 0.76 | USP30 (0.46) | USP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214339-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214339-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | USP30 2708/4885HDAC2 3097/4885GPR119 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.